Vulvar cancer is a rare type of malignancy affecting the external female genitalia, accounting for a small percentage of all gynaecologic cancers. According to the American Cancer Society, vulvar cancer most commonly develops on the inner edges of the labia majora or minora, though it can impact any part of the external female genitalia including the clitoris and perineum.
Understanding Vulvar Cancer Risk Factors and Human Papillomavirus
Medical research identifies several distinct risk factors that increase the likelihood of developing vulvar malignancies. According to the Centers for Disease Control and Prevention, persistent infection with high-risk strains of human papillomavirus (HPV) serves as a primary catalyst for a specific subset of vulvar squamous cell carcinomas, particularly in younger patients. Beyond viral infections, chronic inflammatory conditions of the skin, such as lichen sclerosus, significantly elevate long-term malignant risk by causing persistent cellular changes in the vulvar tissue.
Additional documented risk factors include:
- Advanced age, with the majority of diagnoses occurring in women over the age of 50.
- A personal history of cervical, vaginal, or anal dysplasia and associated cancers.
- Smoking tobacco, which weakens immune function and impairs the body’s ability to clear viral infections like HPV.
- Immunocompromising conditions, including HIV or immunosuppressive therapies following organ transplantation.
Clinical Presentation and Diagnostic Evaluation
Patients with vulvar cancer frequently experience persistent symptoms that mimic benign dermatological conditions, which can delay formal diagnosis. According to clinical guidance from the NHS, common warning signs include a persistent lump, thickening, or a sore ulcer on the vulva that does not heal over several weeks. Other frequently reported clinical manifestations involve persistent pruritus (itching), burning sensations, unexplained bleeding not related to menstruation, or noticeable skin color changes such as hyperpigmentation or depigmentation.
When a patient presents with these warning signs, gynaecological specialists perform a detailed physical examination and utilize a specialized magnifying instrument called a colposcope to inspect the vulvar tissue closely. A definitive diagnosis requires a surgical biopsy, where a small tissue sample is extracted and examined under a microscope by a pathologist to confirm malignancy and determine the specific histological subtype.
Treatment Approaches and Management Strategies
Treatment plans for vulvar cancer depend heavily on the stage of the disease at diagnosis, the depth of invasion, and the patient’s overall health status. According to guidelines published by the National Comprehensive Cancer Network, primary treatment modalities typically involve surgical intervention ranging from a wide local excision to radical vulvectomy, alongside evaluation of the regional lymph nodes to check for metastasis. In cases where the cancer is locally advanced or where organ preservation is a primary clinical goal, radiation therapy and chemotherapy may be utilized either as primary definitive treatments or as adjuvant therapies following surgery.
Prognosis correlates directly with early detection and prompt medical intervention. Women experiencing persistent, unexplained vulvar symptoms are advised to seek evaluation from a primary care physician or a gynaecologist to rule out malignancy and receive targeted dermatological or oncological care.